(A) Diagram of experimental scheme. Chimeras were made by mixing CD45.2+ WT or Ltbr-/- BM cells with CD45.1+ wild-type cells at a 30:70 ratio and injecting into irradiated CD45.1+ recipients. After 8 weeks of reconstitution, mice were immunized with NP-CGG/Alum two times 21 days apart and analyzed 28 days after the booster immunization. (B) FACS plots of singlet cells with a gate on live Dump-B220+ cells (top row, left). The B220+ cells were further gated on IgD+GL7- FO B cells (top row, middle), with further gates on CD45.2+ or CD45.1+ cells (top row, right). Alternatively, B220+ cells were gated based on CD38-GL7+ GC B cells (middle row, left) with further gates on CD45.2+ or CD45.1+ cells (middle row, middle). NP+ GC B cells were identified as NP16-PE+ and decoy SA-PE-AF647- (middle row, right). Memory B cells were identified as CD38+GL7-CD95+IgD- (bottom row, left) with gates on CD45.2+ or CD45.1+ cells (bottom row, middle) or NP+ memory B cells (bottom row, right). (C) Chimerism based on the ratio of CD45.2+ WT or Ltbr-/- to CD45.1+ WT FO B cells (top). GC B cell ratio of CD45.2+ cells to CD45.1+ cells normalized to the FO B cell ratio (middle). Memory B cell ratio of CD45.2+ cells to CD45.1+ cells normalized to the FO B cell ratio (bottom). (D) Representative FACS plots of CD138-enriched BM cells from a CD45.2+ WT recipient chimera pre-gated on live Dump-B220loCD138+ cells. PCs were identified as B220- (left), TACI+CD98+ (top row, middle) with gates on CD45.2+ or CD45.1+ cells (top row, right). NP-CGG+ PCs were identified as NP-CGG-FITC+ (bottom row, left) with further gates on CD45.2+ or CD45.1+ cells (bottom row, right). (E) Ratio of CD45.2+ cells to CD45.1+ cells normalized to the FO B cell ratio for spleen PCs (top) or BM PCs (bottom). Data shown in all panels are representative of two independent experiments (n = 4–5 mice per group).